Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
3 Healthcare Stocks That Pay You While You Wait for the Growth
07:45pm, Monday, 27'th Apr 2026
It may not seem like it at first, but these dividends are safe.
Will These 5 Drug Bigwigs Surpass Q1 Earnings Forecasts?
01:15pm, Monday, 27'th Apr 2026
LLY, MRK, ABBV, BMY and BIIB are set to report this week as recent beats and key drug demand set up a pivotal Q1 earnings test for pharma giants.
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
11:01am, Monday, 27'th Apr 2026
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exploring Analyst Estimates for Bristol Myers (BMY) Q1 Earnings, Beyond Revenue and EPS
10:15am, Monday, 27'th Apr 2026
Get a deeper insight into the potential performance of Bristol Myers (BMY) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for
Is Bristol Myers Squibb the Best Bargain in Big Pharma?
05:50am, Monday, 27'th Apr 2026
This pharma stock is cheap for a reason.
Ashton Thomas Private Wealth LLC Trims Stock Holdings in Bristol Myers Squibb Company $BMY
04:04am, Monday, 27'th Apr 2026
Ashton Thomas Private Wealth LLC lowered its holdings in shares of Bristol Myers Squibb Company (NYSE: BMY) by 18.2% in the undefined quarter, according to its most recent Form 13F filing with the Sec
Bristol-Myers Squibb: 'Strong Buy' As 2026 Milestones Could Bolster Its Prospects
03:46am, Monday, 27'th Apr 2026
Bristol-Myers Squibb retains a "Strong Buy" rating, driven by robust Growth Portfolio expansion and strategic pipeline execution. The company's growth portfolio now nears 60% of total revenues, growin
Bristol Myers Squibb: Low Volatility Meets High Dividend Yield
03:45pm, Sunday, 26'th Apr 2026
Volatility and dividend yield are important metrics for investors thinking about a long-term buy.
Advisors Capital Management LLC Raises Stake in Bristol Myers Squibb Company $BMY
04:26am, Sunday, 26'th Apr 2026
Advisors Capital Management LLC increased its position in Bristol Myers Squibb Company (NYSE: BMY) by 2.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the S
3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery
01:30am, Saturday, 25'th Apr 2026
Some shareholders are waiting for healthcare stocks to rebound. As they wait, some companies pay out dividends with meaningful yields that make that waiting easier.
Dividend Champion, Contender, And Challenger Highlights: Week Of April 26
08:45pm, Friday, 24'th Apr 2026
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?
03:26pm, Friday, 24'th Apr 2026
BMY heads into Q1 earnings with strong growth portfolio momentum, but legacy drug declines and generic pressure may weigh on overall revenue performance.
Bristol Myers, Pfizer Bring Eliquis to Cost Plus at $345 Monthly
12:34pm, Friday, 24'th Apr 2026
Mark Cuban's push to reshape drug pricing is picking up momentum as Bristol Myers Squibb (BMY) and Pfizer (PFE) move to bring Eliquis onto the Mark Cuban Cost P
Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy
08:36am, Friday, 24'th Apr 2026
Bristol-Myers Squibb and Pfizer said on Friday they will start selling their jointly developed blood thinner through billionaire entrepreneur Mark Cuban's online pharmacy beginning April 27.
Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
06:59am, Friday, 24'th Apr 2026
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Eliquis--Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company.
